Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial

BACKGROUND AND OBJECTIVES: In the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG Outcome), empagliflozin, in addition to standard of care, significantly reduced risk of cardiovascular death by 38%, hospitalization for heart failure by 35%, and inciden...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin J Am Soc Nephrol
Main Authors: Levin, Adeera, Perkovic, Vlado, Wheeler, David C., Hantel, Stefan, George, Jyothis T., von Eynatten, Maximilian, Koitka-Weber, Audrey, Wanner, Christoph
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7536760/
https://ncbi.nlm.nih.gov/pubmed/32994159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.14901219
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados